GHP Q2 2018

2 GHP / Q2 2018 Editor’s Note , Welcome to the Q2, 2018 issue of GHP Magazine, bringing you the latest news and features from across the healthcare and pharmaceutical industries. In recent news, on the 9th May 2018, the Metro Atlanta Chamber, Georgia Global Health Alliance and Deloitte announced the launch of Global Health ATL as a collaborative initiative designed to drive Atlanta’s reputation as the “centre for global health.” The initiative’s priorities are to create a health innovation hub in the heart of metro Atlanta and drive impact in areas such as disease eradication, economic development and disaster response. In this month’s issue, Intas Pharmaceuticals announced European Commission approval and completion of its purchase of an Out-licensing basket of products from TEVA. We profiled the transaction as we aim to find out more about Intas’ ongoing achievements. Also in this edition, Urology Partners is dedicated to providing all of its patients with expert advice, patient choice and the very highest quality of clinical care. We spoke to the practice’s four consultants, Neil Barber, Simon Bott, Richard Hindley and Timothy Nedas who each explains what services are offered by the team. Elsewhere in this edition, we take a closer look at how Royal Philips, a global leader in health technology, and US-based Emory Healthcare announced on the 11th May 2018 the launch of a new remote Intensive Care Unit (eICU) monitoring program. The program will be based at the Royal Perth Hospital in Western Australia, and is focused on improving the outcomes of high risk patients and advancing the globalisation of critical care. Here at GHP Magazine, we sincerely hope that you enjoy reading this edition and look forward to hearing from you. Jessie Daykin, Editor Phone: +44 (0) 203 3970 0037 Email: [email protected] Website: www.ghp-magazine.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.